Simon Crabb is a Professor of Experimental Cancer Therapeutics within the School of Cancer Sciences and an Honorary Consultant in Medical Oncology at University Hospital Southampton NHS Foundation Trust. His research is focused on novel treatment options for cancer. This includes interests in precision medicine approaches for bladder and prostate cancers, mechanisms of cancer therapy resistance and epigenetic therapeutics. Professor Crabb is the Associate Clinical Director of Southampton Clinical Trials Unit and Clinical Programme Lead for Southampton Experimental Cancer Medicine Centre. His external roles have included Chairmanship of the Genomics England Clinical Interpretation Partnership for bladder cancer and memberships of the NCRI Bladder and Renal Group, the NCRI Prostate Group and the Experimental Medicine Expert Review Panel for Cancer Research UK.
- Bladder cancer
- Prostate cancer
- Predictive biomarkers
- Precision medicine
- Early phase cancer clinical trials
Prof Crabb is an active contributor to the UK academic clinical trials portfolio with interests that span from first in human through to definitive phase III studies and with a strong emphasis on translational endpoints. He is the Chief Investigator for multiple clinical trials in urological malignancies.
External roles and responsibilities
Prof Crabb graduated in Medicine from St George’s Hospital Medical School in 1996 and joined the University in 2002 as a Cancer Research UK Clinical Research Fellow. His PhD was awarded in 2006 for research on the pre-clinical development of histone deacetylase inhibitors. This was followed by post-doctoral training as a Clinical Research Fellow at the BC Cancer Agency in Vancouver and the Cancer Research UK Centre in Southampton. He was appointed as an Honorary Consultant in Medical Oncology at University Hospital Southampton NHS Foundation Trust in 2009, with specialist clinical interests in bladder, prostate and adrenal cancers. He is a lead for early phase cancer clinical trials for solid malignancies and established the UHS early phase cancer trials clinic.